UK Government Increases Capital Access To Scale Up Biotechs
Life Sciences Investment Programme Launched
The UK government claims there is a lack of later-stage funds investing consistently at scale into the country's life sciences sector and believes a £200m scheme, supplemented by investment from Abu Dhabi, will provide a significant boost to the industry.
You may also be interested in...
Taking full control of partner Translate Bio means that Sanofi is the only big vaccine company with a wholly-owned mRNA platform in-house but observers say it is too early to declare that the Paris-headquartered group has bagged itself a bargain.
Fears that US regulators would take issue with AstraZeneca's decision to change the endpoints of a second pivotal trial for anifrolumab were unfounded and the first-in-class type I interferon inhibitor is the first new treatment for systemic lupus erythematosus in more than 10 years.
The German biotech has raised a significant sum to advance its T-cell therapies for solid tumors developed using its transgenic mouse technology platform.